Literature DB >> 8875574

A preliminary study on the attenuation of Tunisian schizont-infected cell lines of Theileria annulata.

M A Darghouth1, L Ben Miled, A Bouattour, T R Melrose, C G Brown, M Kilani.   

Abstract

Four Theileria annulata cell lines were characterised at low passage levels using two polymorphic markers and then used to infect calves. Their virulence seemed to be related to the number of genotypes present within the cell line. In all, 3 of the 4 cell lines were cultured up to passage 100 or 200 and inoculated into calves. Their characterisation using the same markers indicated that the attenuation was related to a reduction in the parasite polymorphism down to a single genotype. The immunogenicity of the three attenuated cell lines was assessed in calves using two types of challenge. Optimal protection was observed against homologous challenges. The level of immunity to heterologous challenges appeared to decrease with attenuation and seemed to depend on the cell line used.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875574     DOI: 10.1007/s004360050179

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  12 in total

1.  Extensive polymorphism and evidence of immune selection in a highly dominant antigen recognized by bovine CD8 T cells specific for Theileria annulata.

Authors:  Niall D MacHugh; William Weir; Alison Burrells; Regina Lizundia; Simon P Graham; Evans L Taracha; Brian R Shiels; Gordon Langsley; W Ivan Morrison
Journal:  Infect Immun       Date:  2011-02-07       Impact factor: 3.441

2.  Immunological analysis of aerobic bioreactor bovine theileriosis vaccine.

Authors:  Gholamreza Habibi; Kasra Esmaeil-Nia; Hasan Izadi; Orang Ataie Amarloie; Asghar Afshari; Nadia Bordbar
Journal:  Iran J Parasitol       Date:  2014-09       Impact factor: 1.012

3.  Sequence Polymorphism of Cytochrome b Gene in Theileria annulata Tunisian Isolates and Its Association with Buparvaquone Treatment Failure.

Authors:  Moez Mhadhbi; Melek Chaouch; Kaouthar Ajroud; Mohamed Aziz Darghouth; Souha BenAbderrazak
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

4.  The level of H₂O₂ type oxidative stress regulates virulence of Theileria-transformed leukocytes.

Authors:  Mehdi Metheni; Nadia Echebli; Marie Chaussepied; Céline Ransy; Christiane Chéreau; Kirsty Jensen; Elizabeth Glass; Frédéric Batteux; Frédéric Bouillaud; Gordon Langsley
Journal:  Cell Microbiol       Date:  2013-10-21       Impact factor: 3.715

5.  Engineering attenuated virulence of a Theileria annulata-infected macrophage.

Authors:  Nadia Echebli; Moez Mhadhbi; Marie Chaussepied; Catherine Vayssettes; James P Di Santo; Mohamed Aziz Darghouth; Gordon Langsley
Journal:  PLoS Negl Trop Dis       Date:  2014-11-06

Review 6.  Approaches to vaccination against Theileria parva and Theileria annulata.

Authors:  V Nene; W I Morrison
Journal:  Parasite Immunol       Date:  2016-12       Impact factor: 2.280

7.  Population Genetic Analysis of the Theileria annulata Parasites Identified Limited Diversity and Multiplicity of Infection in the Vaccine From India.

Authors:  Sonti Roy; Vasundhra Bhandari; Madhumanti Barman; Pankaj Kumar; Vandna Bhanot; Jaspreet Singh Arora; Satparkash Singh; Paresh Sharma
Journal:  Front Microbiol       Date:  2021-01-20       Impact factor: 5.640

Review 8.  Prevention of tick-borne diseases: challenge to recent medicine.

Authors:  Dominika Hromníková; Daniel Furka; Samuel Furka; Julio Ariel Dueñas Santana; Táňa Ravingerová; Vanda Klöcklerová; Dušan Žitňan
Journal:  Biologia (Bratisl)       Date:  2022-03-09       Impact factor: 1.653

9.  Evaluation of a simple Theileria annulata culture protocol from experimentally infected bovine whole blood.

Authors:  M Gharbi; R Latrach; L Sassi; M A Darghouth
Journal:  Parasite       Date:  2012-08       Impact factor: 3.000

10.  Demonstration of strain-specific CD8 T cell responses to Theileria annulata.

Authors:  N D Machugh; A C Burrells; W I Morrison
Journal:  Parasite Immunol       Date:  2008-08       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.